Sector News

Akorn’s CEO bows out after failing last-ditch bid to save Fresenius merger

December 11, 2018
Life sciences

Akorn once again tried and failed to salvage its $4.3 billion merger with Fresenius. Delaware’s top court ruled that Fresenius had nixed the deal legally after data problems cropped up, and in the wake of the decision, Akorn’s CEO made his exit.

Only days after lawyers for Akorn and Fresenius argued in Delaware Supreme Court, the justices backed a lower court’s decision in Fresenius’ favor. With the ruling, Akorn CEO Raj Rai said he would step down.

The decision follows months of legal back-and-forth over the $4.3 billion deal inked last year. Fresenius agreed to pay $34 per share for the company, but after an investigation turned up data integrity problems at Akorn, Fresenius backed out. Akorn’s shares have fallen more than 85% since February.

Akorn sued to save the deal, and after a lower court ruled for Fresenius in October, appealed to Delaware’s top court. Last week, Akorn lawyers contended that Fresenius knew the risks of the buyout and should be forced to proceed. Fresenius’ attorney pushed back, saying investigators found more problems at every turn at Akorn.

With the court’s decision, Akorn will forge ahead as an independent company; the drugmaker said Rai is retiring and will stay with the company until it can find a successor.

Akorn Chairman Alan Weinstein said the company recognizes “that this has been an extended period of uncertainty for Akorn’s customers, employees and investors, and the board is committed to ensuring the company’s stability and long-term growth.”

Amid the legal battle, Akorn’s share price has tumbled to about $4.25, from about $33 last year.

When Fresenius struck the buyout, it touted the acquisition as a “strategically complementary combination” that would diversify its portfolio and expand its sterile manufacturing capacity. The buy would add three U.S. manufacturing sites to Fresenius’ network, plus another in India, and about 2,000 employees.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach